The Trump Administration’s controversial rule to lower drug prices by basing Medicare Part B reimbursement on the lowest prices paid in other developed countries will probably not go into effect as planned on the first of January; a reprieve will come from the courts or the Administration itself, several health policy experts predicted.
Four separate lawsuits opposing the rule have been filed by biopharma and health care providers. Oral arguments in support of...